Q-omics provides the consensus-scored RPL14P6 profile across patient tissues and cancer cell-line models. RPL14P6 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL14P6 is differentially expressed in 7, with the highest sampling consensus in UCEC. Additionally, RPL14P6 RNA expression shows 6,561 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, UCEC, and STAD as cancer lineages where RPL14P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL14P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL14P6 survival associations across molecular data types. RPL14P6 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL14P6 RNA expression–survival associations across cancer types. High RPL14P6 expression shows unfavorable associations in KIRC, THCA, DLBC and STAD, but favorable associations in UCS and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL14P6 RNA expression.
This table summarizes RPL14P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL14P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL14P6 shows lower tumor expression in THCA and higher tumor expression in UCEC, HNSC, KIRP, PRAD and KIRC. The UCEC box plot shows higher RPL14P6 RNA expression in tumor versus normal tissue (log2 FC = +0.233, t-test p < 0.001).
This table shows molecular features associated with RPL14P6 in patient tissues and cancer cell lines. In patient samples, RPL14P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
